Biotech - Spark Newswire

3 minute read

Onconova Therapeutics Provides Update Oh Phase 1/2 Trial Of Rigosertib-Nivolumab Combination; Says Expansion Of Trial Underway At Highest Dose

Today, 11:58 AM

Expansion of trial underway at highest dose in the current protocol, and continued dose escalation under consideration Preliminary data support the preclinical observation of rigosertib augmenting the response to

ONTX

3 minute read

Nanomedicine Company Makes “Nanomachines” that Attack Viruses

By Kim Griffin

Today, 11:58 AM

Photo by Fusion Medical Animation on Unsplash

MRNA

1 minute read

Eiger BioPharmaceuticals Highlights Presentation Of Phase 2 Results Of Avexitide In Congenital Hyperinsulinism At American Diabetes Association Virtual 81st Scientific Session

By Bill Haddad

Today, 11:58 AM

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced

EIGR

2 minute read

Teva And Bioeq Announce Commercial Partnership For FYB201; Financial Terms Not Disclosed

By Bill Haddad

Today, 11:58 AM

Agreement includes commercializing biosimilar candidate of ophthalmology drug ranibizumab (Lucentis®) in Europe, Canada, Israel and global markets Teva Pharmaceutical Industries Ltd. (NYSE:AND) and Bioeq AG

AND

2 minute read

Daré Bioscience Announces Phase 1 Results For DARE-HRT1; Says Drug ‘demonstrated the ability to deliver two different active pharmaceutical ingredients’ Over 28-Day Period

By Bill Haddad

Today, 11:58 AM

Results Support Potential as the First Monthly Therapy for both the Vasomotor and the Vaginal Symptoms of Menopause The First Clinical Study Using the Novel Segmented Intravaginal Ring (IVR) Technology Validates its

DARE

1 minute read

Arbutus Biopharma Stock Jumps On Encouraging Data From Hepatitis B Candidate

By Vandana Singh

Today, 11:58 AM

Arbutus Biopharma Corporation (NASDAQ: ABUS) announced the presentation of five abstracts at the European Association for the Study of the Liver International Liver Congress for AB-729 in chronic hepatitis B and AB-836 programs.

ABUS

1 minute read

Orphazyme To Cut Two-Third Workforce Under Restructuring; Reaffirms FY21 Outlook

By Vandana Singh

Today, 11:58 AM

ORPH

1 minute read

Novo Nordisk’s Higher Dose Of Semaglutide Trumped 1-mg Predecessor On Blood Sugar, Weight Reduction

By Vandana Singh

Today, 11:58 AM

Novo Nordisk A/S (NYSE:NVO) announced data from SUSTAIN FORTE Phase 3b trial comparing semaglutide 2.0 mg versus 1.0 mg dose as…

NVO

1 minute read

Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate

By Vandana Singh

Today, 11:58 AM

Intellia Therapeutics Inc (NASDAQ:NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have announced positive interim data from an ongoing Phase 1 study of NTLA-2001, which…

NTLA